Analyst Price Targets — LEVI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 4, 2026 5:53 am | Blake Anderson | Jefferies | $25.00 | $19.42 | StreetInsider | Jefferies Starts Levi Strauss & Co. (LEVI) at Buy |
| January 12, 2026 2:11 pm | — | UBS | $33.00 | $21.44 | TheFly | Levi Strauss price target raised to $33 from $32 at UBS |
| December 23, 2025 9:48 am | — | Raymond James | $26.00 | $21.23 | TheFly | Levi Strauss initiated with an Outperform at Raymond James |
| October 14, 2025 8:27 pm | — | BTIG | $27.00 | $21.38 | TheFly | Levi Strauss initiated with a Buy at BTIG |
| October 10, 2025 10:33 am | — | UBS | $32.00 | $24.54 | TheFly | Levi Strauss price target raised to $32 from $28 at UBS |
| October 3, 2025 2:16 pm | — | Telsey Advisory | $27.00 | $24.57 | TheFly | Levi Strauss price target raised to $27 from $24 at Telsey Advisory |
| October 2, 2025 11:17 am | — | Stifel Nicolaus | $27.00 | $24.40 | TheFly | Levi Strauss price target raised to $27 from $24 at Stifel |
| September 26, 2025 8:36 am | — | Barclays | $26.00 | $23.02 | TheFly | Levi Strauss price target raised to $26 from $24 at Barclays |
| July 11, 2025 10:31 am | Ike Boruchow | Wells Fargo | $25.00 | $21.95 | TheFly | Levi Strauss price target raised to $25 from $22 at Wells Fargo |
| May 14, 2025 10:30 am | Ike Boruchow | Wells Fargo | $22.00 | $17.74 | TheFly | Levi Strauss price target raised to $22 from $20 at Wells Fargo |
Latest News for LEVI
Industria de Diseno Textil (OTCMKTS:IDEXY - Get Free Report) and Levi Strauss and Co. (NYSE: LEVI - Get Free Report) are both retail/wholesale companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership. Profitability This table compares
NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Shareholder rights firm Levi & Korsinsky, LLP is investigating potential securities law violations by Vistagen Therapeutics, Inc. (NASDAQ: VTGN) and reminds investors of the March 16, 2026 deadline to seek lead plaintiff status. THE INVESTIGATION: The firm is examining whether Vistagen and certain officers made false or misleading statements during the period from April 1,…
Time-Sensitive: Allegations Focus on Ready-to-Drink Market Competition Representations NEW YORK, Feb. 25, 2026 /PRNewswire/ -- "Investors deserve transparency about material risks that could affect their investments," stated Joseph E. Levi, Esq.
Time-Sensitive: Allegations Focus on Repeated Assurances Regarding Setrusumab Efficacy RARE INVESTOR ALERT "Investors deserve transparency about material risks that could affect their investments," stated Joseph E. Levi, Esq.
Shareholders Who Purchased During the Class Period Urged to Review Options NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 prohibit making untrue statements of material facts or omitting material information necessary to make statements not misleading. A class action pending against Mereo BioPharma Group plc (NASDAQ: MREO) invokes these provisions,…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LEVI.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.